The tweet was deleted by the author.
But we saved everything 🙂.
Arvinas announced its earnings results for the third quarter of 2026.
The company shared this financial update with investors and the public, providing insight into its recent business performance. Further details can be accessed through the provided link.
View post on X Loading...
Earlier this year, Arvinas reported the first approval of a PROTAC protein degrader, broadening prospects for targeted protein degradation therapies (see article). The company also reinstated its Early Career Researcher Award, providing a $25,000 grant to support emerging researchers in the field (see article). These initiatives underline Arvinas’s continuing focus on innovation within targeted protein degradation.